BIIB BIOGEN INC.

Price Chart

Executive Summary

Stifel upgraded Biogen (BIIB) to Buy from Hold on November 6, 2025, raising its price target 40% to $202 from $144, part of a 13-firm cluster re-rating the stock. Stifel's track record shows 54% accuracy on 2,792 calls with a 4.3% average return, placing it near the median among covering firms. Consensus remains cautious: only 20 of 43 analysts rate Buy or Strong Buy, while 22 rate Hold and 1 Sell. The mean price target of $212.51 implies 12% upside from $189.28, with Stifel's $202 sitting below consensus. Recent momentum is positive—three upgrades in the past month from UBS, Wells Fargo, and Piper Sandler—but EPS estimates for 2026 have been revised down 8% over 30 days. Insider selling of $665k from a C-suite executive in February contrasts with institutional buying: Norges Bank initiated a $464M position and FMR doubled its stake. Short interest of 58% suggests heavy bearish positioning, which could amplify a positive catalyst. The bottom line: the upgrade is part of a broader shift, but mixed fundamentals and high short interest warrant a neutral tactical stance until next earnings on July 29, 2026.

Impact Score

Consensus & Targets

Of the 43 analysts covering BIIB, 9 rate Strong Buy, 11 Buy, 22 Hold, 1 Sell, and 0 Strong Sell — a 47% Buy/Strong Buy ratio. Consensus leans cautious, with the majority (51%) at Hold. Stifel's upgrade brings it in line with the bullish minority but above the consensus centre.

Current price: $189.28. Mean target: $212.51 (12% upside). Median: $207. High: $275 (45% upside). Low: $150 (21% downside). Stifel's $202 target is 5% below the mean, suggesting a more conservative bullish view than the average analyst.

Recent Analyst Activity

Over the past 30 days, BIIB has received 3 upgrades (UBS, Wells Fargo, Piper Sandler) and 0 downgrades. EPS revisions for the current fiscal year show 5 upward vs 7 downward revisions over 30 days, with consensus EPS falling 8% from $15.75 to $14.51. Near-term Q2 2026 estimates have also been cut, indicating downward earnings pressure.

Firm Track Record — Stifel

Stifel accuracy: 54% on 2792 calls | avg return: 4.3%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.

Stifel has a 54% accuracy rate on 2,792 calls with an average return of 4.3%. Among covering firms, Jefferies (100% on 2 calls) and Morgan Stanley (83% on 6) have superior accuracy but limited sample sizes. Stifel's accuracy is near the 50% average and its return is above the median, reflecting consistent but not standout performance.

Earnings Estimates

Next earnings: Jul 29, 2026

Cross-Platform Signals

Insider activity: one buy ($585) by officer Murphy Nicole in February 2026, but two sells totaling $666k by executive Singhal Priya. Institutional moves: Norges Bank opened a $464M position, FMR increased 632%, while Wells Fargo trimmed 32% and Renaissance sold 59%. Short interest is 58% of float, a high bearish bet that could fuel a squeeze if positive catalysts emerge. No congressional trades recorded.

Documents Analyzed

Report based on filing metadata.

US Market Status